HARNESS THERAPEUTICS LIMITED

11532498
Active United Kingdom

Research and experimental development on biotechnology

26 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
H

HARNESS THERAPEUTICS LIMITED

11532498

Research and experimental development on biotechnology

Founded 22 Aug 2018 Active United Kingdom 26 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

TRANSINE THERAPEUTICS LIMITED 22 Aug 2018 — 22 Jan 2024
Accounts Submitted 18 Apr 2026 Next due 30 Sept 2026 2 months remaining
Confirmation Submitted 26 Aug 2025 Next due 4 Sept 2026 2 months remaining
Net assets £-9M £6M 2025 year on year
Total assets £5M £4M 2025 year on year
Total Liabilities £14M £2M 2025 year on year
Charges None No charges registered

Contact & Details

Contact

Website

www.example.com

Full company profile for HARNESS THERAPEUTICS LIMITED (11532498), an active life sciences and medical technology company based in United Kingdom. Incorporated 22 Aug 2018. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 2 months remaining

Net Assets, Total Assets & Total Liabilities (2019–2025)

Cash in Bank

£3.60M

Increased by £844.38k (+31%)

Net Assets

-£8.67M

Decreased by £5.64M (-186%)

Total Liabilities

£13.71M

Increased by £2.09M (+18%)

Turnover

N/A

Employees

26

Increased by 2 (+8%)

Debt Ratio

272%

Increased by 137 (+101%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
31 Dec Year End
2024
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

4 Allotments 10,691 Shares £11.10m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
20 Apr 20223,479£4.60m£1k
11 Mar 20223,913£4.50m£1k
4 Aug 20201,739£2.00m£1k
26 Oct 20181,560£3k£2.18

Officers

Officers

1 active 2 resigned
Status
Paulo FontouraDirectorPortugueseSwitzerland5616 Sept 2024Active

Shareholders

Shareholders (14)

Takeda Ventures, Inc
27.5%
4,910
Dementia Discovery General Partner Llp, Acting As General Partner Of Dementia Discovery Gp Lp, Acting As General Partner Of Dementia Discovery L.p
22.7%
4,052

Persons with Significant Control

Persons with Significant Control (2)

2 Active 2 Ceased

Takeda Pharmaceutical Company Limited

Japan

Active
Notified 28 Jan 2020
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent
Active
Notified 16 Nov 2023
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent

Piero Carninci

Ceased 4 Aug 2020

Ceased

Stefano Gustincich

Ceased 4 Aug 2020

Ceased

Group Structure

Group Structure

HARNESS THERAPEUTICS LIMITED Current Company

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
18 Apr 2026AccountsAnnual accounts made up to 31 Dec 2025
18 Apr 2026AccountsAnnual accounts made up to 31 Dec 2025
3 Oct 2025ResolutionResolutions
26 Aug 2025Confirmation StatementConfirmation statement made on 21 Aug 2025 with no updates
10 Jun 2025OfficersTermination of Alan Keith Boyd as director on 5 Jun 2025
18 Apr 2026 Accounts

Annual accounts made up to 31 Dec 2025

18 Apr 2026 Accounts

Annual accounts made up to 31 Dec 2025

3 Oct 2025 Resolution

Resolutions

26 Aug 2025 Confirmation Statement

Confirmation statement made on 21 Aug 2025 with no updates

10 Jun 2025 Officers

Termination of Alan Keith Boyd as director on 5 Jun 2025

Recent Activity

Latest Activity

Annual accounts made up to 31 Dec 2025

2 months ago on 18 Apr 2026

Annual accounts made up to 31 Dec 2025

2 months ago on 18 Apr 2026

Resolutions

9 months ago on 3 Oct 2025

Confirmation statement made on 21 Aug 2025 with no updates

10 months ago on 26 Aug 2025

Termination of Alan Keith Boyd as director on 5 Jun 2025

1 years ago on 10 Jun 2025